ABIOMED, Inc.

If you purchased ABIOMED, Inc. securities and would like to join the action, please click "Join This Action" below.

ABMD STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF ABIOMED, INC. IS FAIR TO SHAREHOLDERS

November 1, 2022.

New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ABIOMED, Inc. (NASDAQ: ABMD) to Johnson & Johnson is fair to ABIOMED shareholders. Under the terms of the agreement, ABIOMED shareholders would receive $380.00 per share in cash and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

The investigation concerns whether ABIOMED and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for ABIOMED shareholders; (2) determine whether Johnson & Johnson is underpaying for ABIOMED; and (3) disclose all material information necessary for ABIOMED shareholders to adequately assess and value the merger consideration. On behalf of ABIOMED shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top